Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality

详细信息    查看全文

• 作者：Alexis Vrachimis ; Burkhard Riemann…
• 关键词：Differentiated thyroid cancer ; 131I Ablation ; TSH levels ; Prognosis
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：43
• 期：2
• 页码：224-231
• 全文大小：471 KB
• 参考文献：1.Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol. 1977;50:799–807.PubMed CrossRef
  2.Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.PubMed CrossRef
  3.Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.PubMed CrossRef
  4.Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.PubMed CrossRef
  5.Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v214–9.PubMed CrossRef
  6.Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T. Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology. 1997;138:2227–32.PubMed CrossRef
  7.Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol. 2000;167:125–35.PubMed CrossRef
  8.Ajjan RA, Kamaruddin NA, Crisp M, Watson PF, Ludgate M, Weetman AP. Regulation and tissue distribution of the human sodium iodide symporter gene. Clin Endocrinol (Oxf). 1998;49:517–23.CrossRef
  9.Wagner S, Aust G, Schott M, Scherbaum WA, Feldkamp J, Seissler J. Regulation of sodium-iodide-symporter gene expression in human thyrocytes measured by real-time polymerase chain reaction. Exp Clin Endocrinol Diabetes. 2002;110:398–402.PubMed CrossRef
  10.Napoli R, Biondi B, Guardasole V, D'Anna C, De Sena A, Pirozzi C, et al. Enhancement of vascular endothelial function by recombinant human thyrotropin. J Clin Endocrinol Metab. 2008;93:1959–63.PubMed CrossRef
  11.Vrachimis A, Schober O, Riemann B. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Nuklearmedizin. 2012;51:67–72.PubMed CrossRef
  12.Vrachimis A, Riemann B, Gerss J, Maier T, Schober O. Peace of mind for patients with differentiated thyroid cancer? Nuklearmedizin. 2013;52:115–20.PubMed CrossRef
  13.Vrachimis A, Gerss J, Stoyke M, Wittekind C, Maier T, Wenning C, et al. No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer. Clin Endocrinol (Oxf). 2014;80:911–7.CrossRef
  14.Rahbar K, Hutzenlaub V, Fischer RJ, Schober O, Riemann B. Risk-profile and outcome of small papillary and follicular thyroid carcinomas (<1 cm). Nuklearmedizin. 2008;47:188–93.PubMed
  15.Verburg FA, Mader U, Luster M, Reiners C. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. Eur J Endocrinol. 2009;160:619–24.PubMed CrossRef
  16.Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, et al. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:276–83.PubMed CrossRef
  17.Verburg FA, Mader U, Luster M, Reiners C. Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2009;71:291–7.CrossRef
  18.Verburg FA, Mader U, Tanase K, Thies ED, Diessl S, Buck AK, et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab. 2013;98:172–80.PubMed CrossRef
  19.Verburg FA, Mader U, Reiners C, Hanscheid H. Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical (131)I therapy in both high- and low-risk patients. J Clin Endocrinol Metab. 2014;99:4487–96.PubMed CrossRef
  20.Tanase K, Thies ED, Mader U, Reiners C, Verburg FA. The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2015. doi:10.​1111/​cen.​12765
  21.Thies ED, Tanase K, Maeder U, Luster M, Buck AK, Hanscheid H, et al. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:2281–90.PubMed CrossRef
  22.Maier TM, Schober O, Gerss J, Gorlich D, Wenning C, Schaefers M, et al. Differentiated thyroid cancer patients more than 60 years old paradoxically show an increased life expectancy. J Nucl Med. 2015;56:190–5.PubMed CrossRef
  23.Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell; 2009.
  24.Rendl J, Grelle I, Reiners C. Methodical properties and clinical efficiency of a novel Tg-assay in the follow-up of differentiated thyroid carcinomas. Nuklearmedizin. 1994;33:A13.
  25.Rodriguez-Espinosa J, Mora-Brugues J, Ordonez-Llanos J, Cortes-Rius M, Queralto-Companyo JM, Gonzalez-Sastre F. Technical and clinical performance of six sensitive immunoradiometric assays of thyrotropin in serum. Clin Chem. 1987;33:1439–45.PubMed
  26.Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.PubMed CrossRef
  27.Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.PubMed CrossRef
  28.Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.PubMed CrossRef
  29.Verburg FA, Mader U, Grelle I, Visser TJ, Peeters RP, Smit JW, et al. The thyroid axis 'setpoints' are significantly altered after long-term suppressive LT4 therapy. Horm Metab Res. 2014;46:794–9.PubMed CrossRef
  30.Uribe RM, Zacarias M, Corkidi G, Cisneros M, Charli JL, Joseph-Bravo P. 17beta-Oestradiol indirectly inhibits thyrotrophin-releasing hormone expression in the hypothalamic paraventricular nucleus of female rats and blunts thyroid axis response to cold exposure. J Neuroendocrinol. 2009;21:439–48.PubMed CrossRef
  31.Verburg F, Weber T, Luster M. 131I sodium-iodide versus 56Fe surgical steel. Which is better for lateral lymph node metastases in differentiated thyroid cancer patients? Nuklearmedizin. 2013;52:113–4.PubMed CrossRef
  32.Hanscheid H, Lassmann M, Buck AK, Reiners C, Verburg FA. The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma. Phys Med Biol. 2014;59:2353–68.PubMed CrossRef
  33.Diessl S, Verburg F, Biko J, Schryen B, Reiners C, Buck A, et al. Improved follow-up of patients with differentiated thyroid carcinoma. The quantitative detection limit of 131I uptake in diagnostic scans. Nuklearmedizin. 2013;52:81–7.PubMed CrossRef
  34.Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–85.PubMed
  35.Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:5686–90.PubMed CrossRef
  36.Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613–9.PubMed CrossRef
  37.Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schopper N, et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol. 2005;153:755–63.PubMed CrossRef
  38.Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15:1147–55.PubMed CrossRef
  39.Borget I, Bonastre J, Catargi B, Deandreis D, Zerdoud S, Rusu D, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. J Clin Oncol. 2015;33:2885–92.PubMed CrossRef
  
• 作者单位：Alexis Vrachimis (1)
  Burkhard Riemann (1)
  Uwe Mäder (2)
  Christoph Reiners (2)
  Frederik A. Verburg (2) (3)
  
  1. Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
  2. Department of Nuclear Medicine, University of Würzburg, Würzburg, Germany
  3. Department of Nuclear Medicine, RWTH University Hospital Aachen, Pauwelsstraße 30, 52074, Aachen, Germany
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nuclear Medicine
  Imaging and Radiology
  Orthopedics
  Cardiology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1619-7089

文摘

Purpose Based on a single older study it is established dogma that TSH levels should be ≥30 mU/l at the time of postoperative 131I ablation in differentiated thyroid cancer (DTC) patients. We sought to determine whether endogenous TSH levels, i.e. after levothyroxine withdrawal, at the time of ablation influence ablation success rates, recurrence-free survival and DTC-related mortality.